A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

Rello J., Krenn C., Locker G., Pilger E., Madl C., Balica L., ...Daha Fazla

CRITICAL CARE, cilt.21, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1186/s13054-017-1601-9
  • Dergi Adı: CRITICAL CARE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Background: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired infections. IC43 has proven immunogenicity and tolerability in healthy volunteers, patients with burns, and patients with chronic lung diseases. In order to assess the immunogenicity and safety of IC43 in patients who are most at risk of acquiring Pseudomonas infections, it was evaluated in mechanically ventilated ICU patients.